calibration and stability of who and secondary viral … lelie - calibration...calibration and...
TRANSCRIPT
Calibration and stability of WHO and secondary viral standards
Nico Lelie, Harry van Drimmelen and the International NAT Study Group
Facilities DDL Diagnostic Laboratories
Outline • Calibration of WHO and secondary standards
– HBV
– HCV
– HIV
– Genotypes
• Stability of secondary standards
– Long term frozen stability at -70°C and -30°C
– In use stability in liquid phase at 4°C, 20°C, 37 °C
• Conclusions
Calibration of HBV standards
Traceability of HBV-DNA standards
Eurohep gt A
1st WHO gt A
2nd WHO gt A
Sanquin-VQC genotype A
Chimp gt A
Eurohep gt D
ISS gt D Chimp gt C
BQC gt A inactivated
WHO gt panel
3rd WHO gt A
BQC gt panel
bDNA calibrators
Dilution, lyophilization
Dilution, pasteurization
Heerman K-H et al. J Clin Microbiol 1999;37:68-73 Saldanha J et al. Vox Sang 2001;80:63-71 Grabarczyk P et al, Transfusion, in press Pisani G et al, Ann Ist Super Sanita 2007:43:69-76 Chudy M et al, J Clin Virol 2012Epub Van Drimmelen et al, unpublished
copies
IUs
ID50
Collins ML, et al. An Biochem 1995;226:120
Komiya K et al. Transfusion 2008;48:286-9
calibrations
Calibration of native Sanquin-VQC HBV standard against WHO 97/746 standard
Experiment n
WHO n
VQC Copy/IU (95% CI)
Parallel Siemens Versant bDNA 3.0 assays (Cuijpers et al Sanquin, Amsterdam)
12 16 5.33
(5.11-5.55)
Parallel Siemens Versant bDNA 3.0 assays (Van Drimmelen, DDL, Rijswijk)
6 6 5.20
(4.61-5.80)
Multi-method WHO Collaborative study (Saldanha J et al. Vox Sang 2001;80:63-71)
46 23 4.12
Grabarczyk P et al, Transfusion, in press Data reported in Supplementary Materials accessible online on Transfusion website
Calibration Japanese Chimpanzee infectivity plasmas against Sanquin-VQC HBV genotype A standard
Chimp plasma
Study Assays n copies/ CID50 (range)
C-246 P-57 genotype A
BQC-DDL
bDNA 3.0
6
4.0 ( 1.3-12.6)
Komiya et al
TaqMan
1
8.2 (2.6-26)
C-272 P-29 genotype C
BQC-DDL
bDNA 3.0
6
5.9 (1.8-18.5)
Komiya et al
TaqMan
1
9.5 (3.0-30)
Komiya K et al. Transfusion 2008;48:286-9 Grabarczyk P et al, Transfusion, in press (data reported in Supplementary Materials accessible online on Transfusion website)
Native VQC HBV-DNA genotype A standard
(2.15 x 109 cps/mL, 6.8 x 108 CID50/mL)
Preparation of pasteurised BQC HBV-DNA plasma standard
100 diluted HBV-DNA standard in PBS
(2.15 x 106 cps/mL )
1:100 dilution in PBS
Pasteurized HBV-DNA standard in PBS
( ~0.6 mg/mL protein)
1:2.5 dilution in plasma
and snap freezing in liquid nitrogen
inactivated BQC HBV-DNA plasma standard
(7.23 x 106 cps/mL, <2.3 CID50/mL)
> 106 CID50
inactivation*
*Lelie PN et al J.Med.Virol. 1987:23:289-95
84%
recovery HBV-DNA
25,000 rpm, 16h, 10°C
Banding of HBV DNA in sucrose gradient
Gerlich et al, SoGAT, Brussels 2009
WHO lyophilised ISS lyophilised BQC pasteurized VQC native
Analytical sensitivity of Ultrio and Ultrio Plus on native and pasteurized HBV-DNA standard
data from Ultrio and Ultrio Plus validation studies in Ireland, Denmark and Poland
Standard
Native
Inactivated 8.86 (3.14-34.9)
Relative sensitivity Ultrio Plus to Ultrio
3.60 (1.45-11.0)
Assay
Ultrio
Ultrio Plus
Relative potency native to inactivated
3.78 (1.53-11.3)
1.54 (0.67-3.74)
Study standard Assay n 95% LOD (CI) 50% LOD (CI)
Ultrio 24 161 (82-378) 15.7 (8.6-28.8)
Ultrio Plus 24 44.7 (22.4-107) 4.4 (2.3-8.2)
Denmark Ultrio 58 699 (337-2301) 55 ((33-93)
Ultrio 24 607 (301-1493) 59 (32-111)
Ultrio Plus 24 68.6 (35.8-159) 6.7 (3.8-11.9)
Poland
Poland
native
inactivated
Potency of native and pasteurized HBV-DNA standard in Ultrio Plus probit and TaqScreen Ct analysis
Assay n native
n inact
analysis Potency inactivated relative to native standard (95% CI)
Ultrio Plus 24 24 probit§ 0,65 (0.27-1.49)
TaqScreen 32 32 Ct# 0.87 (0.76-0.98)
Comparison of Ct values on 2000 cps/mL levels of both standards in parallel TaqScreen test runs performed by Dr Marco Koppelman (Sanquin, Amsterdam) #
§ Study performed by Prof. Piotr Grabarczyk (IHTM, Warsaw, Poland)
bDNA calibration n native n inact cps/mL native cps/mL inact
experiment 6 6 2.15 x 10E9 7.23 x 10E6
Potency of 2nd WHO HBV 97/750 IS relative to 1st 97/746 IS in Ultrio validation studies
standard n Potency (95% CI)
97/746 733 reference
97/750 88 1.14 (0,57-2.35)
IU/mL
% Ultrio reactive
WHO calibration study of Baylis et al (WHO report BS/06/2034 ) showed a not significant lower potency of 0.85 in 97/750 IS relative to 97/746 IS, but unitage was kept at 10E6 IU/ampoule
Comparison potency of HBV genotype A standards in Ultrio Plus (UP above) and TaqScreen (Tx below)
(1 IU = 5.33 copies)
HBV standard n
50% LOD (CI) cps/mL in UP
95% LOD (CI) cps/mL in UP
Potency relative to Eurohep standard
97/746 20 4.0 (2.1-7.8) 29.0 (14.9-58.9) 0.89 (0.43-1.94) 97/750 791 3.7 (3.3-4.1) 26.9 (22.9-32.3) 0.96 (0.67-1.43)
Eurohep 96 3.6 (2.7-4.7) 25.9 (18.9-36.3) 1.00 (reference) Chimp 48 3.7 (2.5-5.7) 27.2 (17.7-42.9) 0.95 (0.57-1.58)
VQC native 60 5.0 (3.4-7.2) 36.3 (24.6-54.8) 0.71 (0.45-1.14) BQC inact 24 6.6 (3.6-11.9) 48.3 (26.6-89.9) 0.54 (0.28-1.03)
HBV standard n
50% LOD (CI) cps/mL in Tx
95% LOD (CI) cps/mL in Tx
Potency relative to Eurohep standard
97/746 224 4.1 (3.6-4.7) 20.9 (17.9-25.1) 0.54 (0.31-0.98) Eurohep 12 2.6 (1.3-3.8) 11.4 (6.6-20.4) 1.00 (reference)
VQC native 12 2.8 (1.7-4.7) 14.2 (8.5-24.8) 0.80 (0.38-1.65)
Calibration of HIV standards
Preparation pasteurized and/or lyophilized HIV-RNA reference samples
native standard in plasma 1.05 x 108 cps/ml
1:10 dilution in PBS 2h hour 65 0C
pasteurized 1:10 in PBS
1:10 dilution in plasma
1:100 diluted 1:100 diluted pasteurized
1:100 dilution in plasma
1:100 dilution in plasma
1:10,000 diluted pasteurized 1:10,000 diluted native freeze-drying
freeze-drying
freezing freezing
regular lyophilized
1:100 dilution in plasma
pasteurized past./lyophilized
Recovery of HIV-RNA after pasteurization and/or lyophilization
process standard Average cps/mL*
recovery
Native standard 15,542§ 100%
lyophilization 3810 24%
pasteurization 8988 56%
pasteurization & lyophilization 3634 23%
* Geometric mean values of 18 Bayer Versant bDNA assays for each process
§ cultured HIV diluted in plasma to 10,500 cps/mL as determined by 58 bDNA assays in 7 test runs
Potency of native and pasteurized HIV-RNA standard in Ultrio probit and TaqScreen Ct analysis
Study standard n 95% LOD (CI) 50% LOD (CI)
Poland native 12 15.3 (8.8-29.2) 2.1 (1.3-3.5)
Denmark inactivated 52 22.2 (15.6-34.5) 3.1 (2.4-3.9)
Assay n native
n inact
analysis Potency inactivated relative to native standard (95% CI)
Ultrio 12 52 probit§ 0,69 (0.38-1.22)
TaqScreen 40 40 Ct# 1.04 (0.86-1.22)
Comparison of Ct values on 2000 cps/mL levels of both standards in parallel TaqScreen test runs performed by Dr Koppelman (Sanquin)
§
#
bDNA calibration n native n inact cps/mL native cps/mL inact
experiment 6 6 1.05 x 10E8 2.62 x 10E6
Assay
N assays cps/IU on 1st WHO (97/656) standard
cps/IU on 2nd WHO (97/650) standard
1st WHO
2nd WHO
VQC mean (95%CI) mean (95%CI)
Abbott LCx
14 15 14 0.76 (0.60-0.96) 0.69 (0.56-0.86)
Roche Amplicor Monitor
125 134 112 0.70 (0.60-0.81) 0.93 (0.80-1.08)
Siemens bDNA 3.0
64 69 48 0.39 (0.34-0.44) 0.58 (0.51-0.66)
Organon Tekika NucliSens
46 51 36 0.80 (0.69-0.92) 0.43 (0.36-0.50)
Roche Amplicor Mon UltraSens
16 15 11 0.51 (0.27-0.95) 0.86 (0.49-1.51)
Calibration of VQC-Sanquin HIV-RNA subtype B standard on the first (97/656) and second (97/650) WHO HIV-1 RNA subtype B standards
calculated from raw data reported by the laboratories participating in the first WHO collaborative study
Holmes H et al, J. Virological Methods 2001, 92; 141-150 Grabarczyk P et al, Transfusion, in press ((Table reported in Supplementary Materials accessible online on Transfusion website)
IU/mL
% TMA reactive
standard n Potency (95% CI)
97/650 718 reference
97/656 131 1.00 (0,77-1.30)
PWS 99/634 581 0.91 (0.77-1.06)
Potency of 1st HIV-1 97/656 IS and PWS 99/634 relative to 2nd 97/650 IS in TMA assay validation studies
Assay Standard n
dHIV 97/656 48
Duplex 97/656 83
Ultrio 97/650 94
Ultrio Elite 97/650 231
Ultrio Plus 97/650 393
Duplex PWS-1 99/634 48
Ultrio PWS-1 99/634 533
Calibration of HCV standards
Calibration 3rd HCV WHO 06/100 IS, 06/102 sample and unlyophilised bulk on 2nd 96/798 IS
Data Baylis S et al, Vox Sang 2011, 100, 409-417
quantitative assays
n labs IS 96/798 IS 06/100 06/102 unlyophilised sample 2 sample 3 sample 4
Abbott RT 7 1,00E+05 1,82E+05 2,88E+05 4,57E+05
Siemens bDNA 4 1,00E+05 1,58E+05 2,19E+05 2,95E+05
Roche CTM 6 1,00E+05 1,51E+05 2,34E+05 3,63E+05
Mean three methods
17 1,00E+05 1,63E+05 2,45E+05 3,66E+05
recovery lyophilisation 45%* 67% 100%
Overall mean six methods report
25 1,00E+05 1,55E+05 2,57E+05 5,01E+05
recovery lyophilisation 31% 51% 100%
Factor value three methods different from overall values in report
1,06 0,95 0,73
*40% in Abbott core antigen
standard n Potency (95% CI)
96/798 594 reference
96/790 48 1.04 (0,71-1.50)
06/100 750 0.78 (0.67-0.89)*
% TMA reactive
IU/mL
Potency of 3rd 06/100 and 1st 96/790 IS relative to 2nd 96/798 IS in TMA assay validation studies
Assay standard n
Ultrio 06/100 86
Ultrio Elite 06/100 245
Ultrio Plus 06/100 419
Duplex 96/790 24
Ultrio 96/790 24
Duplex 96/798 72
Ultrio 96/798 522
* 06/100 vs 96/798, p<0.05
Study standard n 95% LOD (CI) 50% LOD (CI)
Poland native 12 14.6 (8.3-28.6) 1.9 (1.1-3.2)
Denmark inactivated 52 28.1 (19.4-45.3) 3.6 (2.8-4.7)
Potency of native and inactivated HCV-RNA standard in Ultrio probit and TaqScreen Ct analysis
Assay n native
n inact
analysis Potency inactivated relative to native standard (95% CI)
Ultrio 12 52 probit§ 0,52 (0.27-0.92)
TaqScreen 32 32 Ct# 0.45 (0.31-0.58)
§
Comparison of Ct values on 2000 cps/mL levels of both standards in parallel test runs performed by Dr. Koppelman (Sanquin, Amsterdam, Netherlands)
#
bDNA calibration n native n inact cps/mL native cps/mL inact
1st experiment 6 12 6.30 x 10E7 6.06 x 10E7*
2nd experiment 3 3 6.30 x 10E7 4.11 x 10E7*
* 1.47 fold lower in repeat experiment
Calibration of viral genotype standards
Example of calibration of HBV genotype standards in multiple DNA 3.0 assays
Secondary HBV-DNA standard
bDNA 3.0 runs cps/ml 95% CI (cps/ml) 95% CI (%)
N assays
N exp
df weighted avarage
lower upper lower upper
VQC gt A 28 4 20 2.15E+09 2.11E+09 2.20E+09 98% 102% Chimp gt A 6 1 4 1.26E+06 7.30E+05 2.16E+06 58% 172%
Eurohep gt A 6 1 4 2.97E+09 1.78E+09 4.95E+09 60% 167% DDL gt B 9 3 3 1.94E+09 1.62E+09 2.33E+09 83% 120% DDL gt C 9 3 3 2.21E+09 1.87E+09 2.61E+09 85% 118%
Chimp gt C 6 1 4 1.85E+06 1.28E+06 2.67E+06 69% 144% DDL gt D 9 3 3 3.46E+09 2.95E+09 4.06E+09 85% 117%
Eurohep gt D 12 2 8 2.53E+09 2.03E+09 3.17E+09 80% 125% ISS gt D 3 1 1 3.91E+04 8.77E+03 1.75E+05 22% 446% DDL gt E 9 3 5 1.57E+09 1.42E+09 1.74E+09 90% 111% DDL gt F 9 3 5 1.43E+09 9.18E+08 2.23E+09 64% 156% DDL gt G 9 3 5 8.29E+06 6.89E+06 9.97E+06 83% 120%
Grabarczyk P et al, Transfusion, in press Data reported in Supplementary Materials accessible online on Transfusion website
1
10
100
A B C D AE O 1 2 3 4 5 6 A B C D E F G
1
10
100
A B C D AE O 1 2 3 4 5 6 A B C D E F G
1
10
100
A B C D AE O 1 2 3 4 5 6 A B C D E F G
cp
s/m
L
cp
s/m
L
cp
s/m
L
HIV-1 subtypes HCV genotypes HBV genotypes
HIV-1 subtypes HCV genotypes HBV genotypes
Ultrio
Ultrio PLus
TaqScreen
63% detection limits in copies/mL
Adapted from Assal et al. Transfusion 2009;49:289-300
1%
10%
100%
1000%
A B C D AE O 1 2 3 4 5 6 A B C D E F G
1%
10%
100%
1000%
A B C D AE O 1 2 3 4 5 6 A B C D E F G
1%
10%
100%
1000%
A B C D AE O 1 2 3 4 5 6 A B C D E F G
% e
ffic
ien
cy
% e
ffic
ien
cy
% e
ffic
ien
cy
HIV-1 subtypes HCV genotypes HBV genotypes
HIV-1 subtypes HCV genotypes HBV genotypes
Ultrio % detection efficiency
Ultrio Plus
TaqScreen
Fig 2
TaqScreen Ct values on HIV-1 subtype B standard dilution series
Data set from Assal et al.Transfusion. 2009;49:301-310
low variation suitable
for run control
Large variation; Poisson distribution
Slope equals -1.0 indicating
PCR efficiency is 100 %
Below LOD
Marker genotype Potency Ct analysis Potency probit analysis
HBV-DNA
genotype A 100 % 100 % genotype B 53 (43-65)% 38 (14-96) % genotype C 66 (54-81)% 54(21-136)% genotype D 254(230-282)% 184(85-419)% genotype E 285(254-319)% 133(61-295)% genotype F 41(76-93)% 53(24-113)% genotype G 84(76-93)% 40(17-84)%
HCV-RNA
genotype 1 100 % 100 % genotype 2 138 (130-147)% 127(64-259)% genotype 3 106(98-114)% 179(91-372)% genotype 4 22(20-23)% 34(14-69)% genotype 5 45(41-50)% 48(22-96)% genotype 6 80(73-87)% 53(25-106)%
HIV-1 RNA
subtype B 100 % 100 % subtype A 137(121-155)% 132(71-260)% subtype C 126(112-142)% 136(74-267)% CRF01_AE 69(59-80)% 134(73-261)%
Comparison of TaqScreen Ct and probit analysis
BQC 100 and 1000 cps/mL subgenotype panels for HBV, HCV and HIV NAT assays
Panel
nr
Standard Origin HBV
genotype
Panel
nr
Standard Origin HCV
genotype
Panel
nr
Standard Origin HIV subtype
1 WHO-PEI South Afr A1 1 Sanquin-VQC Netherlands 1a,b 1 BQC Netherlands A
2 WHO-PEI Brazil A1 2 BQC-INTS Egypt 1a 2 Sanquin-VQC Netherlands B
3 Sanquin-VQC Netherl A2 3 ARC USA 1a 3 BQC Netherlands C
4 Eurohep Germany A2 4 JRC Japan 1b 4 BQC Netherlands D
5 WHO-PEI Germany A2 5 JRC Japan 1b 5 BBI Brazil F
6 BQC Indonesia B 6 JRC Japan 2a 6 BBI Romania F
7 WHO-PEI Japan B2 7 JRC Japan 2a 7 BBI Zaire G
8 WHO-PEI Japan B2 8 BQC Netherlands 2a,b 8 BBI Kenya G
9 WHO-PEI Vietnam B4 9 JRC Japan 2b 9 BBI Zaire H
10 BQC USA C 10 JRC Japan 2b 10 BQC Netherlands CRF01_AE
11 WHO-PEI Japan C2 11 BQC Netherlands 3a 11 BBI Thailand CRF01_AE
12 WHO-PEI Japan C2 12 BQC-INTS Lithuania 3a 12 BBI Ghana CRF01_AG
13 WHO-PEI Russia C2 13 BQC-INTS Lithuania 3a 13 BBI Camaroon group O
14 BQC USA D 14 BQC-INTS Thailand 3b 14 BBI Camaroon group O
15 Eurohep Germany D 15 BQC Netherlands 4 15 BBI USA group O
16 ISS Italy D 16 BQC-INTS Egypt 4a 16 BBI Spain group O
17 WHO-PEI Germany D1 17 BQC USA 4a 17 BQC Belgium HIV-2 A
18 WHO-PEI South Afr D3 18 BQC Congo 4c 18 BQC Cameroon group O
19 WHO-PEI Iran D1 19 BQC Congo 4e 19 BQC Cameroon group N
20 BQC West Afr E 20 BQC USA 5a
21 WHO-PEI West Afr E 21 BQC USA 6a
22 BQC USA F 22 BQC USA 6a
23 WHO-PEI Brazil F3 23 BQC Thailand 6n
24 BQC USA G
25 WHO-PEI Germany G
P0138 HBV genotype panel 100 cps/mL P0139 HCV genotype panel 100 cps/mL P0137 HIV subtype panel 100 cps/mL
Long term stability of liquid frozen secondary viral standards
at -70°C and -30°C
Stability Sanquin-VQC HBV-DNA genotype A plasma standard at -70°C
Test year n Copies/mL
average 95% CI lower
95% CI upper
bDNA 1.0
1996 9 3.73E+09
1997 2 2.38E+09
1998 4 2.94E+09 1.46E+09 5.92E+09
1999 2 2.69E+09
average 17 3.22E+09 3.20E+09 3.24E+09
bDNA 3.0
2001 16 2.15E+09 1.77E+09 2.62E+09
2006 3 2.07E+09 1.45E+09 2.96E+09
2006 3 1.40E+09 5.63E+08 3.47E+09
2008 6 2.71E+09 2.06E+09 3.57E+09
average 28 2.15E+09 2.10E+09 2.20E+09
Stability Sanquin-VQC HCV-RNA genotype 1 plasma standard (anti-HCV+) at -70°C
Test year n Average
copies/mL 95% CI lower
95% CI upper
bDNA 1.0 1996 4 8.76E+06 raw data not available
bDNA 2.0
1997 3 1.17E+07 3.50E+05 3.89E+08
1998 4 6.31E+06 5.45E+06 7.30E+06
1999 1 7.01E+06
2000 5 9.59E+06 3.49E+06 2.63E+07
2000 30 1.06E+07 7.10E+06 1.58E+07
average 43 9.83E+06 9.41E+06 1.03E+07
bDNA 3.0
2001 8 6.21E+06 3.97E+06 9.71E+06
2003 6 6.43E+06 4.68E+06 8.84E+06
2003 3 6.77E+06 1.35E+06 3.40E+07
2004 4 8.45E+06 3.65E+06 1.96E+07
2008 6 5.00E+06 3.83E+06 6.52E+06
average 27 6.30E+06 6.13E+06 6.48E+06
Test year n Copies/mL
average 95% CI lower
95% CI upper
bDNA 1.0 1997 13 4.71E+07
bDNA 2.0
1999 18 1.14E+08 5.79E+07 2.25E+08 1999 31 1.06E+08 6.95E+07 1.61E+08
2000 8 1.13E+08 5.06E+07 2.53E+08
Average 57 1.09E+08 1.05E+08 1.14E+08
bDNA 3.0
2001 3 8.75E+07 3.55E+07 2.16E+08
2002 6 1.63E+08 1.18E+08 2.25E+08
2002 33 9.66E+07 5.71E+07 1.64E+08
2002 2 1.66E+08
2003 6 8.99E+07 6.73E+07 1.20E+08
2004 2 4.18E+07 2008 6 1.56E+08 1.14E+08 2.14E+08
average 58 1.05E+08 1.01E+08 1.09E+08
Stability Sanquin-VQC HIV-1 RNA subtype B (cultured) plasma standard at -70°C
Stability of native HCV and HIV-1 plasma standards at -70°C confirmed in Ultrio LODs
study year
HCV-RNA genotype 1 LOD in copies/mL
HIV-RNA subtype B LOD in copies/mL
95% (CI) 50% (CI) 95% (CI) 50% (CI)
Lelie et al1 2000 25 (19-35) 2.3 (1.8-2.9) 13 (8-22) 1.5 (1.1-2.1)
Koppelman et al2 2004 25 (14-72) 2.9 (1.9-1.8) 21 (12-52) 2.4 (1.8-3.2)
Vermeulen et al3 2009 8.3 (5-15) 1.3 (0.9-1.8)
Grabarczyk et al4 2010 15 (8-37) 2.3 (1.4-3.8) 17 (8-47) 1.9 (1.1-3.2)
1. Lelie et al. Transfusion 2002;2:27-536) 2. Koppelman et al. Transfusion 2005;45:1258-1266 3. Vermeulen et al. Transfusion 2013 Epub 4. Grabarczyk et al. Transfusion 2013 Epub
Comparison four years stability of secondary HCV standard (a-HCV+) at -30° and -70°C
-70°C -30°C
number assays* 12 12
geomean 124,451 126,814
95% CI upper 102,332 113,107
95% CI lower 151,350 140,936
*Siemens Versant bDNA assay 3.0
Stability of frozen HIV (cultured) plasma standards at -70°C and -30°C in EasyQ
-70°C
-30°C
Slope-0.029 (NS)
Slope-0.123
10% degradation per year at -30°C 0
In use stability of secondary viral standards in liquid phase
at 4°C, 20°C and 37 °C
Impact of lyophilization and pasteurization on HIV-RNA short term stability in liquid phase
Temp Time
(hours) copies/mL in bDNA 3.0 assay
liquid. lyoph. inact. lyoph.
20°C 0 15164 3299 8463 3010
20°C 8 15004 3515 9170 3591
20°C 24 14703 3096 8697 3805
4°C 0 17439 4250 9208 3380
4°C 8 16209 4307 9344 4359
4°C 24 16715 4656 9077 3801
Temp Time
(hours) copies/mL in bDNA 3.0 assay
liquid. lyoph. inact. lyoph.
20°C 0 100% 100% 100% 100%
20°C 8 99% 107% 108% 119%
20°C 24 97% 94% 103% 126%
4°C 0 100% 100% 100% 100%
4°C 8 93% 101% 101% 129%
4°C 24 96% 110% 99% 112%
Impact of lyophilization and pasteurization on HIV-RNA stability in liquid phase
Stability of HIV-RNA run control* at 4°C and room temperature in QT-NASBA
Time (hours)
NA
SBA
Lo
g co
pie
s/m
L
*Cultured native HIV clade B in plasma *QC sample diluted to 10,500 cps/mL in bDNA assay and 33,200 cps/mL in QT-NASBA
74% after 120h
63% after 120h
Log linear regression analysis estimated 15% degradation at 41 and 54 hours for RT and 4°C
at -70°C
Stability native and pasteurized HBV-DNA standards in liquid phase on TaqScreen 2.0*
mean quadruplicate Ct (potency) native HBV-DNA
hours -70°C 2-8°C 20°C 37°C
8 27.97 (100%) 28.02 (97%) 27.77 (115%) 27.87 (107%)
24 28.05 (100%) 28.00 (104%) 27.88 (113%) 27.95 (107%)
48 28.17 (100%) 28.00 (113%) 28.03 (111%) 28.28 (93%)
mean quadruplicate Ct (potency) inactivated HBV-DNA
hours -70°C 2-8°C 20°C 37°C
8 28.20 (100%) 28.18 (102%) 27.98 (117%) 27.93 (121%)
24 28.22 (100%) 28.08 (111%) 27.90 (125%) 27.78 (137%)
48 28.47 (100%) 28.25 (117%) 28.25 (117%) 28.10 (130%)
*2000 cps/mL concentrations were tested in subsequent TaqScreen 2.0 test runs at storage times by Dr Marco Koppelman (Sanquin, Amsterdam, the Netherlands)
Stability HCV gt 1 (a-HCV+) and gt 3 (a-HCV-) standards in liquid phase on TaqScreen 2.0*
mean quadruplicate Ct (potency) native HCV-RNA gt 1
hours -70°C 2-8°C 20°C 37°C
8 30.88 (100%) 30.88 (100%) 31.00 (92%) 31.48 (66%)
24 30.90 (100%) 30.88 (102%) 30.93 (98%) 32.05 (45%)
48 30.93 (100%) 31.23 (81%) 31.13 (87%) 32.38 (37%)
mean quadruplicate Ct (potency) native HCV-RNA gt 3a
hours -70°C 2-8°C 20°C 37°C
8 31.23 (100%) 31.65 (74%) 31.53 (81%) 32.33 (47%)
24 31.20 (100%) 31.55 (78%) 31.55 (78%) 31.93 (60%)
48 31.03 (100%) 31.50 (72%) 31.45 (74%) 32.13 (47%)
*2000 cps/mL concentrations were tested in subsequent TaqScreen 2.0 test runs at storage times by Dr Marco Koppelman (Sanquin, Amsterdam, the Netherlands)
Stability native and inactivated HCV gt 3 WP standards in liquid phase on TaqScreen 2.0*
mean quadruplicate Ct (potency) native HCV-RNA gt 3a
hours -70°C 2-8°C 20°C 37°C
8 31.23 (100%) 31.65 (74%) 31.53 (81%) 32.33 (47%)
24 31.20 (100%) 31.55 (78%) 31.55 (78%) 31.93 (60%)
48 31.03 (100%) 31.50 (72%) 31.45 (74%) 32.13 (47%)
mean quadruplicate Ct (potency) inactivated HCV-RNA gt 3a
hours -70°C 2-8°C 20°C 37°C
8 32.00 (100%) 32.20 (87%) 32.38 (77%) 33.40 (38%)
24 31.83 (100%) 32.25 (74%) 32.63 (57%) 33.33 (35%)
48 31.75 (100%) 32.35 (66%) 32.13 (77%) 33.23 (36%)
*2000 cps/mL concentrations were tested in subsequent TaqScreen 2.0 test runs at storage times by Dr Marco Koppelman (Sanquin, Amsterdam, the Netherlands)
Stability native and inactivated HIV-1 clade B standards in liquid phase on TaqScreen 2.0*
mean quadruplicate Ct (potency) native HIV-RNA clade B
hours -70°C 2-8°C 20°C 37°C
8 29.05 (100%) 29.05 (100%) 28.85 (115%) 29.03 (102%)
24 29.15 (100%) 29.05 (107%) 29.00 (111%) 29.23 (95%)
48 28.75 (100%) 29.25 (71%) 29.15 (76%) 29.80 (48%)
mean quadruplicate Ct (potency) inactivated HIV-RNA clade B
hours -70°C 2-8°C 20°C 37°C
8 28.95 (100%) 28.93 (102%) 28.68 (121%) 29.03 (95%)
24 28.90 (100%) 28.98 (95%) 28.90 (100%) 28.93 (98%)
48 28.78 (100%) 29.30 (69%) 29.20 (74%) 29.45 (63%)
*2000 cps/mL concentrations were tested in subsequent TaqScreen 2.0 test runs at storage times by Dr Marco Koppelman (Sanquin, Amsterdam, the Netherlands)
Safety Assessment of secondary inactivated standards
for NAT blood screening
Inactivation of viral standards for preparation of NAT blood screening run controls
BQC
standard
inactivation
method
before
inactivation
in standard after
inactivation in run controls
cps/mL ID50/
mL cps/mL ID50/mL yield cps/mL ID50/mL
HBV-
DNA
10 hours
pasteurization at
65°C, 1:100
diluted in PBS
2,15
E+09
6,80
E+08
7,23
E+06
<2,30
E+00 84% <500
<1,60
E-04
HCV-
RNA
0.14%
betapropiolactone
for 5 hours at
23°C, 18h 4°C
4,39
E+07
1,38E
+07
4,11
E+07
<4,11
E+03 94% <500
<5,00
E-02
HIV-1
RNA
2 hours
pasteurization at
65°C, 1:10 diluted
in PBS
1,05
E+08
1,66
E+06
2,62
E+06
<6,60
E-01 62% <500
1,27
E-04
Conclusions • WHO HCV 06/100 standard when shipped at RT has lower
potency than 96/798 in TMA field studies.
• Liquid Frozen plasma standards are long term stable at -70°C, but cultured HIV standard degrades at -30°C.
• Calibration of secondary BQC standards is confirmed in NAT blood screening assays, but concentration of inactivated HCV standard needs to be reassessed.
• No indication that lyophilisation and inactivation affect integrity and stability of residual viral particles in plasma standards.
• There may be a subpopulation of less stable virus in a-HCV negative HCV-RNA plasma standards
• Sensitivity of qualitative real time PCR blood screening assays can be predicted with calibrated 1000 cps/mL genotype panels by comparing Ct values